A Review of Gene Editing/Therapy and CRISPR Technology
DOI:
https://doi.org/10.55175/cdk.v46i6.441Keywords:
CRISPR, gene editingAbstract
This review will discuss the gene editing or manipulation in general, including various methods and tools currently available, including CRISPR. Some encouraging results of clinical applications of gene-therapy will also be discussed. With its diverse and far reaching effect on biomedical field, we will also discuss CRISPR technology beyond its gene-editing functions. We also review the cost for performing a gene-therapy.
Ulasan ini membahas penyuntingan atau manipulasi gen umumnya, berbagai cara dan alat yang kini tersedia, termasuk teknologi CRISPR. Akan disajikan pula hasil-hasil percobaan klinik yang memberi harapan. Mengingat pengaruhnya yang luas di bidang biomedis, akan dibahas pula pemanfaatannya di bidang lain. Akhirnya, akan dibicarakan juga hal-hal terkait biaya pengeditan terapi gen yang sangat tinggi, dengan harapan bisa ditekan di masa yang akan datang dengan teknologi yang lebih canggih.
Downloads
References
Watson JD, Crick FHC. Molecular structure of nucleic acids: A structure for deoxyribose nucleic acid. Nature 1953;171:737-8
Heather JM, Chain B. The history of sequencing DNA. Genomics 2016;107:1-8
Thomas CE, Ehrhardt AA, Kay MA. Progress and problems with the use of viral vector for gene therapy. Nat Rev Genet. 2003;4(5):346-58
Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80(1-2):148-58
Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retro-virus mediated gene therapy of SCID-X1. J Clin. Invest. 2008:118(9):3132-42.
Bjerke JN, Beardslee PC, McNaughton BR. Recent advance in CRISPR based editing: From A to RNA. Biochemistry 2018;57:886-7
Wang W, Li W, Ma N, Steinhoff G. Non-viral gene delivering method. Curr Pharm Biotechnol. 2013;14(1):46-60
Dunbar CE. Gene transfer to hematopoietic stem cells: Implications for gene therapy of human disease. Ann Rev Med. 1996;47:11-20
Kotterman MA, Chalberg TW, Schaffer DV. Viral vector for gene therapy: Translational an clinical outlook. Ann Rev Biomed Eng. 2015;17: 63-89
Trobridge GD. Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opin Biol Ther. 2011;11(5):581-593
Yu SF, Ruden TV, Kantoff PW, Garber C, Seiberg M, Ruther U, et al. Self-inactivating retroviral vector designed for transfer of whole genes into mammalian cells. PNAS USA. 1986;83:3194-8
Korin YD, Zack JA. Progression to the G1bphase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcrition in T cells. J Virol. 1998;72:3161-8
May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L, et al. Therapeutic hemoglobin synthesis in beta-thalassemic mice expressing lentivirus-encoded human betaglobin. Nature 2000; 406:82-6
Lusby E, Fife KH, Berns KI. Nucleotides sequence of the inverted terminal repitition in Adeno-associated virus DNA. J Virol. 1980;34(2):402-9
Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol. 2007;36:71-80
Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissues of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70: 8098-108
Carroll D. Genome engineering with zinc finger nucleases. Genetics 2011;188(4):773-82
Carroll D. Progress and prospects: Zinc finger nucleases as gene therapy agents. Gene Ther. 2008;15:1463-8
Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for high throughput genome editing. Nat Biotechnol. 2012;30(5):460-5
Erkes A, Reschke M, Boch J, Grau J. Evolution of transcription activator-like effectors in Xanthomonas oryzae. Genome boil. Evol. 2017;9(6):1599-615.
Pennisi E. The tale of the tales. Science 2012;338:1408-11
Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A, et al. Targeting DNA double strength break with TAL effector nuclease. Genetics 2010;186(2):757-61
Joung JK, Sander JD. TALENs: A widely applicable technology for targeted genome editing. (Box 2 – TALE based transcrition factor). Nat Rev Mol Cell Biol. 2013;14(1):49-55
Zhang F, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P. Efficient construction of sequence specific TAL effectors for Modulating mammalian transcription. Nat Biotechnol. 2011; 29:149-53.
Wikipedia
Doudna JA, Charpentier E. Genome editing: The new frontier of genome engineering with CRISPR-Cas9. Science 2014;346(6213):1258096.
Shmakov S, Abudayyeh OO, Makarova KS, Wolf YI, Gootenberg JS, Semenova E, et al. Discovery and functional characterization of diverse class 2 CRISPR-Cas system. Mol Cell 2015;60(3):385-97
Bao Z, HamediRad M, Xue P, Xiao H, Tasan I, Chao R, et al. Genome-scale engineering of Saccharomyces cerevisiae with single nucleotide precision. Nat Biotechnol. 2018;36(6):505-8.
Tang W, Liu DR. Rewritable multi-event analog recording in bacterial and mammalian cells. Science. 2018;360(6385). pii: eaap8992.
Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6. Science. 2018;360(6387):439-44.
Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded Dnase activity. Science 2018;360(6387):436-9.
Chavez A, Pruitt BW, Tuttle M, Shapiro RS, Cecchi RJ, Winston J, et al . Precise Cas9 targeting enable genomic mutation prevention. Proc Natl Acad Sci U S A. 2018;115(14):3669-73.
Regalado A. Top U.S. intelligence official calls gene editing a WMD threat [Internet]. 2016 Feb 9. Available from: https://technology review.com/s/600774/top-usintelligence-official-calls-gene-editing-a-wmd-threat/#/set/id/600776
Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, et al. A modified gammaretrovirus vector for X-link severe combined immunodeficiencies. N Eng J Med. 2014;371:1407-17
Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with non-myeloablative conditioning. Science 2002;296:2410-13
Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, et al. Gene therapy for Wiskott-Aldrich syndrome-long term efficacy and genotoxicity. Sci Transl Med. 2014;6(227):227ra33
Ramaswamy S, Tonnu N, Menon T, Lewis BM, Green KT, Wampler D, et al. Autologous and heterologous cell therapy for hemophilia B toward functional restoration of factor IX. Cell Rep. 2018;23:1565-80
Martyn GE, Wienert B, Yang L, Shah M, Norton LJ, Burdach J, et al. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nature Genetics 2018;50:498-503
Kaminski R, Chen Y, Fischer T, Tedaldi E, Napoli A, Zhang Y, et al. Elimination of HIV-1genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. Scientific report 2016;6:22555
FDA. December 19, 2017: Senior executives of medical drug repackager sentenced for defrauding healthcare providers. News release [Internet]. 2017 Dec 19. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/criminal-investigations/december-19-2017-seniorexecutives-medical-drug-repackager-sentenced-defrauding-healthcare-providers
Wilson JM. Glybera’s story mirrors that of gene therapy. Gen Engineer Biotechnol News [Internet]. 2013. Available from: https://www.liebertpub.com/doi/10.1089/gen.33.01.25
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
